April 2, 2009
Nuclear Hormone Receptors, MicroRNAs Form Developmental Switch
A particular nuclear hormone receptor called DAF-12 and molecules called microRNAs in the let-7 family form a molecular switch that encourages cells in the larvae of a model worm to shift to a more developed state, said a consortium led by researchers from Baylor College of Medicine (www.bcm.edu) in a report that appears online today in the journal Science (www.sciencemag.org).
As organisms go through the stages of life, hormones coordinate the changes. Nuclear receptors respond to hormones to coordinate stage transitions, but how they do so is not well understood.
Going from stage 2 to stage 3
"We knew that nuclear hormone receptors were involved in stage 2 to stage 3 transitions in Caenorhabditis elegans," said Dr. Adam Antebi (http://www.bcm.edu/mcb/?PMID=8411), associate professor in the Huffington Center on Aging at BCM and the report's senior author. "Another class of molecules called microRNAs is also involved in that transition. We hypothesized that maybe if they are involved in the same process, one turns on the other."
That turns out to be the case in C. elegans and may be true in more advanced organisms as well, he said.
A model worm enables studies
Scientists use the tiny worm called Caenorhabditis elegans to study such processes because it has a simple anatomy and life cycle. C. elegans develops from embryo through four larval stages into adulthood.
Each "stage" has specific programs of cell division, migration, differentiation and death that are crucial to the organism's final development. Particular master regulators in the worm determine each stage transition and are responsible for organizing developmental time.
"Expression of the let-7 family of microRNAs is dependent on the nuclear receptor and its hormone," Antebi said. "We can show in the worm and in cell culture that DAF-12 and its steroid hormone are directly activating these microRNAs."
How transitions occur
But how does this cause stage transitions? The tiny molecules called microRNAs work as switches to turn off other genes. In this case, the nuclear hormone receptor DAF-12 and its ligand turn on the microRNAs, which then turn off the earlier developmental "programming" of the cell (stage 2), allowing the later programming (stage 3) to take over.
`Specifically, the microRNAs dial-back the activity of a protein called "hunchback," which specifies that the cells are in stage 2. That enables stage 3 to start and development to continue.
Provides cancer insights
"We think this could also give insight into cancers," Antebi said, "particularly those that are hormone-dependent, such as breast or prostate cancer. When worm skin cells go from stage 2 to stage 3 they reduce their cell proliferation. When they fail this transition, skin cells overproliferate (grow uncontrollably)."
It is known that both nuclear receptors and microRNAs play a role in human cancers. These studies could help bridge understanding of the effects of the two.
Linking development and environment
Antebi also thinks that this system links development to the environment. DAF-12 plays a role in a long-lived quiescent stage called the dauer diapause, which the worms enter in times of starvation and overcrowding.
"In good times, the DAF-12 steroid ligand is made, the microRNAs are turned on, and the worm goes through all stages of development to adult," said Antebi. (A ligand is a molecule that binds to the receptor to form a biologically active complex.)
"In bad times, the ligand is not made and the nuclear receptor (DAF-12) causes the animals to go into the long lived dauer stage, shutting down the microRNAs and the developmental clock," he said.
In this way, environmental signals actually affect the worm's rate of development, and perhaps even its aging, said Antebi.
Others who took part in this work include Axel Bethke and Nicole Fielenbach of BCM, and Zhu Wang and David J. Mangelsdorf of The University of Texas Southwestern Medical Center in Dallas. Bethke is now with the University of Osnabruck in Germany.
Funding for this work came from the National Institutes of Health, the Ellison Medical Foundation, the Howard Hughes Medical Institute and the Robert Welch Foundation.
On The Net: